Consolidation ahead for pharma, Merck chief says

Sign Merck ($MRK) CEO Ken Frazier up for the no-megamergers pledge. At a financial conference, Frazier said he expects more consolidation in the pharma business because of a "redundancy of infrastructure," but Merck will focus on targeted deals to gain access to "the best of science" outside the company. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.